A Phase 1 Combined Single and Multiple Ascending Intravenous Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MA-0217 in Healthy Adult Subjects and Healthy Elderly Subjects
Latest Information Update: 02 Nov 2021
Price :
$35 *
At a glance
- Drugs ASP 1128 (Primary)
- Indications Acute kidney injury
- Focus Adverse reactions
- Sponsors Astellas Pharma Europe Ltd
- 10 Feb 2021 New trial record